Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Libevitug (HH-003) in Chronic Hepatitis B with Low-Level Viremia
NCT05734807Phase 2Completed
- Sponsor
- Huahui Health
- Start
- Jul 2022
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Libevitug in Chronic Hepatitis B (CHB) (3 arms), sponsored by Huahui Health. Primary endpoints: Percentage of subjects with HBV DNA negativation at 24 weeks and Changes from baseline in serum HBsAg at 48 weeks. Started Jul 2022; status: completed.
02
Drugs
Libevitug
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05734807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05734807.